Stock comparison

BMYvsRPRX

Bristol-Myers Squibb CovsRoyalty Pharma PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

RPRX

Royalty Pharma PLC

$49.64

+29.34%

Pharmaceuticals$27.1BNASDAQ

60-day price, rebased to 100

BMY +8.73% · RPRX +19.10%

Round-by-round

BMY 3·RPRX 2· 1tie

EdgeBMY

Valuation upside

+2.90% vs -57.50% to DCF fair value

Tie

Balance-sheet strength

Altman Z 2.20 vs 2.25

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 5.00 (of 9)

EdgeRPRX

Growth + margins

Rule-of-40 26.40 vs 109.80

EdgeRPRX

60-day momentum

+8.73% vs +19.10% price return

EdgeBMY

Market-cap liquidity

$117.4B vs $27.1B

Verdict

Across6categories,BMYtakes the edge with3wins to2 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorRPRX

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.